CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Perflutren lipid microspheredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02684435
NCT02684435Phase 2Completed
CompareCT.gov

Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD (CEUS CKD)

University of North Carolina, Chapel Hill·interventional·Posted Feb 18, 2016·Updated Sep 26, 2019

In Brief

A Phase 2 clinical trial evaluating Perflutren lipid microsphere for Chronic Kidney Disease and Cystic Kidney Disease. Completed, enrolled 63 participants across 2 sites.

Detailed Summary

The purpose of this research study is to evaluate contrast-enhanced ultrasound for kidney malignancies

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, Cystic Kidney Disease
CountriesUnited States
CollaboratorsVanderbilt University, North Carolina Translational and Clinical Sciences Institute

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 18, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJul 9, 2018
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.4 years ago

Interventions

Perflutren lipid microspheredrug

Dosing per approved package label